Secura Bio Acquires WW Commercialization Rights to Novartis’ Farydak for R/R Multiple Myeloma

 Secura Bio Acquires WW Commercialization Rights to Novartis’ Farydak for R/R Multiple Myeloma

Secura Bio Acquires WW Commercialization Rights to Novartis’ Farydak for R/R Multiple Myeloma

Shots:

  • Secure Bio to get WW commercialization rights for Farydak (panobinostat) from Novartis to treat patients with r/r multiple myeloma with no prior treatment
  • The focus of the acquisition is to expand Secura Bio’s oncology portfolio and develop new product combinations for Farydak
  • Farydak (panobinostat, PO) is a histone deacetylase (HDAC) inhibitor & decreases the growth of myeloma cells. On February 23 & August 28, 2015, it has received the FDA’s accelerated approval & EU’s approval for the same indication and is marketed in 53 countries

Click here to read full press release/ article | Ref: PRNewswire | Image: Secura Bio

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post